Chris LoBianco

Healthcare

Limited coverage. Only 7 questions of coverage. Treat these numbers as directional — sample too small for reliable averages.

Companies

Questions

Challenge RatePercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions.

Challenge Trend

Q4 '24Q1 '26

Focus Areas8 topics

Innovation & R&D3Product Launch3Demand2M&A1Capital Allocation1Competitive Dynamics1Revenue Growth1Trade Tariffs1

Trends5 quarters

Questions per Quarter

Questions

Challenging

Companies Covered

Question History7 questions

ZTSZoetis5 quarters

2026 Q1

What is Zoetis' level of interest and confidence in FTC approval of large-scale transformational business development

M&ACapital AllocationView in transcript →

potential to pull forward filings for some of the newer market products like renal and oncology

Innovation & R&DProduct LaunchView in transcript →

2025 Q4

Could you just give us an update on where you are in the approval process for Lanivia with the FDA?

Innovation & R&DProduct LaunchView in transcript →

What initial feedback are you hearing from vet KOLs on the safety profiles of Lanivia and Portela?

Product LaunchCompetitive DynamicsView in transcript →

2025 Q3

How doable are these growth drivers as you look ahead to 2026

Revenue GrowthDemandView in transcript →

2025 Q2

has Animal Health been granted an exemption from recently announced EU pharma tariffs? And at a high level, are you seeing any impact of the overall tariff environment on consumer share while it's ...

Trade TariffsDemandView in transcript →

2024 Q4

risk-adjusted, the pipeline opportunities with renal and oncology, have these assets generated pivotal data yet? And does Zoetis have multiple shots on goal

Innovation & R&DView in transcript →